Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96(10):1295–312.

Article  PubMed  PubMed Central  Google Scholar 

Abramson JS. Anti-CD19 CAR T-cell therapy for B-Cell non-Hodgkin lymphoma. Transfus Med Rev. 2020;34(1):29–33.

Article  PubMed  Google Scholar 

Martino M, Alati C, Canale FA, et al. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-acute lymphoblastic leukemia. Int J Mol Sci. 2021;22(4):89.

Article  Google Scholar 

Maude SL, Teachey DT, Rheingold SR, et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. J Clin Oncol. 2016;34(15):3011–111.

Article  Google Scholar 

Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghorashian S, Kramer AM, Onuoha S, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25(9):1408–14.

Article  CAS  PubMed  Google Scholar 

Schultz LM, Eaton A, Baggott C, et al. Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia. J Clin Oncol. 2023;41(2):354–63.

Article  CAS  PubMed  Google Scholar 

Roddie C, Dias J, O’Reilly MA, et al. Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. J Clin Oncol. 2021;39(30):3352–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim J, Cho J, Yoon SE, et al. Efficacy of salvage treatments in relapsed or refractory diffuse large B-cell lymphoma including chimeric antigen receptor T-Cell therapy: a systematic review and meta-analysis. Cancer Res Treat. 2023;55(3):1031–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roschewski M, Longo DL, Wilson WH. CAR T-Cell therapy for large B-cell lymphoma - who, when, and how? N Engl J Med. 2022;386(7):692–6.

Article  PubMed  Google Scholar 

Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–15.

Article  CAS  PubMed  Google Scholar 

Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504–6.

Article  CAS  PubMed  Google Scholar 

Hamieh M, Dobrin A, Cabriolu A, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568(7750):112–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu X, Sun Q, Liang X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Plaks V, Rossi JM, Chou J, et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood. 2021;138(12):1081–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–8.

Article  CAS  PubMed  Google Scholar 

Pan J, Niu Q, Deng B, et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia. 2019;33(12):2854–66.

Article  CAS  PubMed  Google Scholar 

Shor B, Gerber H-P, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67(2):107–16.

Article  CAS  PubMed  Google Scholar 

Shah NN, Stevenson MS, Yuan CM, et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62(6):964–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah NN, Highfill SL, Shalabi H, et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J Clin Oncol. 2020;38(17):1938–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Summers C, Baxter B, Annesley C, et al. CD22 CAR optimization for improved in-human activity following inadequate CD22 CAR activity in phase 1 clinical trial PLAT-04. Blood. 2021;138(Supplement 1):403–503.

Article  Google Scholar 

Zhu H, Deng H, Mu J, et al. Anti-CD22 CAR-T Cell therapy as a salvage treatment in B cell malignancies refractory or relapsed after anti-CD19 CAR-T therapy. Onco Targets Ther. 2021;14:4023–37.

Article  PubMed  PubMed Central  Google Scholar 

Jain N, Roboz GJ, Konopleva M, et al. Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood. 2021;138(Supplement 1):1746–846.

Article  Google Scholar 

Baird JH, Frank MJ, Craig J, et al. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. Blood. 2021;137(17):2321–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frank MJ, Baird JH, Patel S, et al. CD22-CAR T-Cell therapy mediates high durable remission rates in adults with large B-cell lymphoma who have relapsed after CD19-CAR T-Cell Therapy. Blood. 2021;138(Supplement 1):741–841.

Article  Google Scholar 

Myers RM, DiNofia AM, Li Y, et al. CD22-Targeted CAR-Modified T-cells safely induce remissions in children and young adults with relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells. Blood. 2022;140(Supplement 1):2376–7.

Article  Google Scholar 

Tan Y, Cai H, Li C, et al. A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL. Blood Cancer J. 2021;11(4):71.

Article  PubMed  PubMed Central  Google Scholar 

Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther. 2006;6(10):1341–53.

Article  CAS  PubMed  Google Scholar 

Clark EA, Giltiay NV. CD22: a regulator of innate and adaptive B cell responses and autoimmunity. Front Immunol. 2018;9:2235.

Article  PubMed  PubMed Central  Google Scholar 

Nitschke L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev. 2009;230(1):128–43.

Article  CAS  PubMed  Google Scholar 

Ramya TNC, Weerapana E, Liao L, et al. In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics. Mol Cell Proteomics. 2010;9(6):1339–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

FitzGerald DJ, Wayne AS, Kreitman RJ, et al. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Can Res. 2011;71(20):6300–9.

Article  CAS  Google Scholar 

Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165–74.